Hybio Pharmaceutical and BrightGene Pharmaceutical Enter into Strategic Cooperation to Safeguard Overseas Supply Chains for Innovative Drugs
July 31, 2025, Suzhou - Shenzhen Hybio Pharmaceutical Co., Ltd. and Brightgene Bio-Medical Technology Co.,Ltd. signed a strategic cooperation agreement today in Suzhou regarding the cooperation on peptide raw materials for Brightgene's innovative drugs in overseas commercialization. Zeng Shaogui, Chairman of Hybio Pharmaceutical, Yuan Jiandong, Chairman of Brightgene pharmaceutical, and project teams from both parties attended the ceremony.
In this cooperation, Hybio Pharmaceutical will give full play to its own advantages to provide solid overseas raw material supply guarantee for Brightgene pharmaceutical's metabolic pipelines, especially oral peptide products, and establish a long-term and stable strategic cooperative relationship, so as to support the global industrialization of Brightgene's innovative drugs.
Zeng Shaogui stated, "This cooperation is an important milestone for Hybio to undertake international peptide innovative drugs, and also a verification of our global registration and large-scale production capabilities. We look forward to working with Brightgene to help China's original innovative drugs enter the global market."
Yuan Jiandong said, "Hybio Pharmaceutical has a 'peptide API production base' built in accordance with EU and US GMP standards. As one of the largest peptide API production bases in China, it has a production capacity of over ton level, which can fully meet the incremental demand of Brightgene's innovative drugs in overseas markets. We look forward to overseas cooperation with Hybio."
About Hybio Pharmaceutical (300199.SZ)
As a national high-tech enterprise, it has focused on peptide and oligonucleotide drugs for more than 20 years, with integrated international layout capabilities from API to preparations. Its production lines have passed FDA, EMA and NMPA certifications, and its products have entered Europe, America, Asia-Pacific and other countries.
About Brightgene Bio-Medical Technology Co.,Ltd. (688166.SH)
It is an international innovative pharmaceutical enterprise focusing on the fields of metabolic and respiratory diseases. It lays out innovative drug R&D from a global perspective, especially with multiple pipelines advancing in the metabolic field. It has built API and preparation bases in line with EU and US cGMP standards, and its products cover China, the European Union, the United States, Japan, South Korea and other "the Belt and Road" countries or regions.